clonidine has been researched along with Nicotine Addiction in 26 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide." | 8.81 | Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002) |
| "Clonidine's actions and efficacy in mental disorders are reviewed and examined." | 5.06 | Psychiatric indications for clonidine: the neuropharmacologic and clinical basis. ( Bond, WS, 1986) |
| " Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies." | 4.90 | Emerging drugs for the treatment of tobacco dependence: 2014 update. ( Ebbert, JO; Elrashidi, MY, 2014) |
| "Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide." | 4.81 | Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002) |
| " Smoking cessation is difficult due to nicotine addiction and withdrawal symptoms." | 3.76 | Current treatment options in smoking cessation. ( Bhat, A; Crain, D, 2010) |
| " There is strong evidence for the efficacy of the atypical antidepressant Bupropion as therapy for smoking cessation." | 3.75 | [Current and future medical drugs for smoking cessation]. ( Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T, 2009) |
| "Cumulative meta-analyses of five smoking cessation interventions (clonidine, nicotine replacement therapy using gum and patch, physician advice and acupuncture) were used to calculate I2 and H." | 3.72 | Evaluating heterogeneity in cumulative meta-analyses. ( Villanueva, EV; Zavarsek, S, 2004) |
| "Patients with COPD show higher nicotine dependence and seem to have greater difficulty in quitting smoking." | 2.47 | [Smoking in COPD]. ( Bernabé Barrios, MJ; Rodríguez Hermosa, JL; Santamaría Rodríguez, B; Zamarro García, C, 2011) |
| "In addition, new indications for treating tobacco dependence and withdrawal show promise for reducing tobacco use and associated disease." | 2.44 | Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. ( Buchhalter, AR; Fant, RV; Henningfield, JE, 2008) |
| "The outcome of smoking cessation has improved with the availability of proper behavior approaches and medications." | 2.42 | Pharmacotherapy of tobacco dependence. ( Jain, M; Talwar, A; Vijayan, VK, 2004) |
| "Nicotine dependence was induced by implanting minipumps that delivered a nicotine solution." | 1.38 | Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. ( Alexander, JC; Bishnoi, M; Bruijnzeel, AW; Ford, J; Ji, Y; Rogers, JA; Scheick, S, 2012) |
| "Tobacco dependence is a chronic disorder that is characterized by relapse after periods of abstinence." | 1.34 | Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. ( Bruijnzeel, AW; Desai, TV; Prado, M; Shah, HP; Zislis, G, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (19.23) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 7 (26.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vasic, N | 1 |
| Elrashidi, MY | 1 |
| Ebbert, JO | 1 |
| Albertson, TE | 1 |
| Chenoweth, J | 1 |
| Ford, J | 3 |
| Owen, K | 1 |
| Sutter, ME | 1 |
| Kusma, B | 1 |
| Mache, S | 1 |
| Deissenrieder, F | 1 |
| Quarcoo, D | 1 |
| Welte, T | 1 |
| Groneberg, D | 1 |
| Engelmann, JM | 1 |
| Radke, AK | 1 |
| Gewirtz, JC | 1 |
| Crain, D | 1 |
| Bhat, A | 1 |
| Bruijnzeel, AW | 3 |
| Bishnoi, M | 2 |
| van Tuijl, IA | 1 |
| Keijzers, KF | 1 |
| Yavarovich, KR | 1 |
| Pasek, TM | 1 |
| Alexander, JC | 2 |
| Yamada, H | 1 |
| Rogers, JA | 1 |
| Scheick, S | 1 |
| Ji, Y | 1 |
| Zamarro García, C | 1 |
| Bernabé Barrios, MJ | 1 |
| Santamaría Rodríguez, B | 1 |
| Rodríguez Hermosa, JL | 1 |
| Kotlyar, M | 1 |
| Hatsukami, DK | 1 |
| Villanueva, EV | 1 |
| Zavarsek, S | 1 |
| Talwar, A | 1 |
| Jain, M | 1 |
| Vijayan, VK | 1 |
| Schroeder, SA | 1 |
| Hill, A | 1 |
| Cofta-Woerpel, L | 1 |
| Wright, KL | 1 |
| Wetter, DW | 1 |
| Frishman, WH | 1 |
| Zislis, G | 1 |
| Desai, TV | 1 |
| Prado, M | 1 |
| Shah, HP | 1 |
| Buchhalter, AR | 1 |
| Fant, RV | 1 |
| Henningfield, JE | 2 |
| Jasinski, DR | 1 |
| Haertzen, CA | 1 |
| Johnson, RE | 1 |
| Makhzoumi, HM | 1 |
| Miyasato, K | 1 |
| Aparici, M | 1 |
| Fernández González, AL | 1 |
| Alegría, E | 1 |
| Becker, LA | 1 |
| McGee, KH | 1 |
| Murray, KM | 1 |
| Smith, CG | 1 |
| Hao, W | 1 |
| Young, D | 1 |
| Wei, H | 1 |
| Bond, WS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| An Innovative Digital Smoking Cessation Intervention for Low-Income Adults With Substance Use Disorder[NCT04419922] | 100 participants (Actual) | Observational | 2020-04-02 | Active, not recruiting | |||
| Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations[NCT01156610] | 706 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| An Innovation Involving Self-Surveillance and Serious Gaming to Increase Smoking Quit Rate: Protocol for a Randomized Controlled Trial[NCT04630340] | 40 participants (Anticipated) | Interventional | 2021-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (OOWS Scale) (Mean) |
|---|---|
| Placebo | 3.5 |
| Palonosetron | 1.0 |
| Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (SOWS Scale) (Mean) |
|---|---|
| Placebo | 6.0 |
| Palonosetron | 4.0 |
| Palonosetron + Hydroxyzine | 3.5 |
10 reviews available for clonidine and Nicotine Addiction
| Article | Year |
|---|---|
[Smoking cessation].
Topics: Antidepressive Agents; Clonidine; Combined Modality Therapy; Humans; International Classification of | 2013 |
Emerging drugs for the treatment of tobacco dependence: 2014 update.
Topics: Atomoxetine Hydrochloride; Benzazepines; Bupropion; Clinical Trials as Topic; Clonidine; Humans; Mec | 2014 |
Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?
Topics: Adrenergic alpha-2 Receptor Agonists; Alcoholism; Clonidine; Dexmedetomidine; Humans; Opioid-Related | 2014 |
[Smoking in COPD].
Topics: Benzazepines; Bupropion; Clonidine; Comorbidity; Disease Progression; Europe; Humans; Motivation; Ni | 2011 |
Managing nicotine addiction.
Topics: Administration, Inhalation; Adolescent; Adult; Antidepressive Agents, Tricyclic; Bupropion; Chewing | 2002 |
Pharmacotherapy of tobacco dependence.
Topics: Adrenergic alpha-Agonists; Adult; Antidepressive Agents, Second-Generation; Bupropion; Clonidine; Fe | 2004 |
A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Bupropion; Clonidine; Cost-Benefit Analysis; Decis | 2006 |
Smoking cessation 3: multicomponent interventions.
Topics: Behavior Therapy; Bupropion; Clonidine; Combined Modality Therapy; Humans; Motivation; Nicotine; Nor | 2007 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidi | 2007 |
Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Clonidine; Cytochrome P-450 CYP2A6; Drug Deliv | 2008 |
3 trials available for clonidine and Nicotine Addiction
| Article | Year |
|---|---|
[Clonidine in the treatment of tobacco withdrawal. A comparison with nicotine chewing gum].
Topics: Adult; Chewing Gum; Clonidine; Female; Humans; Male; Nicotine; Prospective Studies; Smoking Cessatio | 1994 |
Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Behavior Therapy; Clinical Trials as Topic; Clonidine; C | 1988 |
Psychiatric indications for clonidine: the neuropharmacologic and clinical basis.
Topics: Animals; Anxiety; Bipolar Disorder; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug T | 1986 |
13 other studies available for clonidine and Nicotine Addiction
| Article | Year |
|---|---|
[Current and future medical drugs for smoking cessation].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabi | 2009 |
Potentiated startle as a measure of the negative affective consequences of repeated exposure to nicotine in rats.
Topics: Acoustic Stimulation; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Clonidine; Dose-R | 2009 |
Current treatment options in smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidi | 2010 |
Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antag | 2010 |
Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Amygdala; Animals; | 2012 |
[Smoking, nicotine dependence and detoxification therapies].
Topics: Administration, Cutaneous; Administration, Intranasal; Adrenergic alpha-Agonists; Antidepressive Age | 2002 |
Evaluating heterogeneity in cumulative meta-analyses.
Topics: Acupuncture; Clonidine; Counseling; Data Interpretation, Statistical; Effect Modifier, Epidemiologic | 2004 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Behavior, Animal; Clonidine; Conditioning, | 2007 |
Progress report of the NIDA Addiction Research Center.
Topics: Analgesics; Buprenorphine; Chlordiazepoxide; Clonidine; Diazepam; Humans; Morphine; National Institu | 1982 |
Helping patients quit smoking.
Topics: Clonidine; Counseling; Humans; Lobeline; Nicotinic Agonists; Psychotropic Drugs; Randomized Controll | 1998 |
Clonidine in nicotine withdrawal.
Topics: Administration, Oral; Clonidine; Humans; Nicotine; Substance Withdrawal Syndrome; Tobacco Use Disord | 1989 |
Offers treatment plan for "the most dangerous drug".
Topics: Behavior Therapy; Clonidine; Humans; Tobacco Use Disorder | 1989 |